{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RAYOS&page=36",
    "query": {
      "intervention": "RAYOS",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 1199,
    "total_pages": 120,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RAYOS&page=37&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RAYOS&page=35&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T11:30:50.587Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00384111",
      "title": "Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Follicular Lymphoma",
        "Lymphoma, Follicular"
      ],
      "interventions": [
        {
          "name": "Zevalin Therapeutic Regimen",
          "type": "DRUG"
        },
        {
          "name": "R-CVP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2006-10",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2022-01-14",
      "last_synced_at": "2026-10-26T11:30:50.587Z",
      "location_count": 6,
      "location_summary": "Jacksonville, Florida • St. Petersburg, Florida • Marietta, Georgia + 3 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00384111"
    },
    {
      "nct_id": "NCT01860963",
      "title": "Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anal Squamous Intraepithelial Lesion (ASIL)",
        "HPV DNA"
      ],
      "interventions": [
        {
          "name": "Anal Pap smear and HPV DNA testing",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 310,
      "start_date": "2010-01",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2013-10-01",
      "last_synced_at": "2026-10-26T11:30:50.587Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01860963"
    },
    {
      "nct_id": "NCT07220187",
      "title": "Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Richter Syndrome",
        "Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma",
        "Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Pirtobrutinib",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab and Hyaluronidase Human",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2026-08-04",
      "completion_date": "2036-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-26T11:30:50.587Z",
      "location_count": 62,
      "location_summary": "Irvine, California • Laguna Hills, California • Orange, California + 48 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Bloomington",
          "state": "Illinois"
        },
        {
          "city": "Canton",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220187"
    },
    {
      "nct_id": "NCT00006721",
      "title": "S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "vincristine",
          "type": "DRUG"
        },
        {
          "name": "tositumomab",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 571,
      "start_date": "2001-03",
      "completion_date": "2025-12",
      "has_results": true,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-10-26T11:30:50.587Z",
      "location_count": 259,
      "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 167 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006721"
    },
    {
      "nct_id": "NCT04812366",
      "title": "Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Apalutamide 60mg Tab",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate 250mg",
          "type": "DRUG"
        },
        {
          "name": "Prednisone 5mg Tab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Niraparib 100mg Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Tazemetostat Pill",
          "type": "DRUG"
        },
        {
          "name": "Capivasertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of British Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 315,
      "start_date": "2021-09-21",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-10-26T11:30:50.587Z",
      "location_count": 5,
      "location_summary": "Sacramento, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04812366"
    },
    {
      "nct_id": "NCT01925131",
      "title": "S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Leukemias of Ambiguous Lineage",
        "B-cell Adult Acute Lymphoblastic Leukemia",
        "Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Burkitt Lymphoma"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "inotuzumab ozogamicin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2014-06-13",
      "completion_date": "2023-01-01",
      "has_results": true,
      "last_update_posted_date": "2023-05-03",
      "last_synced_at": "2026-10-26T11:30:50.587Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Palo Alto, California • Rochester, New York + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01925131"
    },
    {
      "nct_id": "NCT06091865",
      "title": "A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma (DLBCL)"
      ],
      "interventions": [
        {
          "name": "Odronextamab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone/Prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 904,
      "start_date": "2023-12-13",
      "completion_date": "2029-09-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-26T11:30:50.587Z",
      "location_count": 23,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Orange, California + 19 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06091865"
    },
    {
      "nct_id": "NCT03414437",
      "title": "Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer Metastatic"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Carolina Research Professionals, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 31,
      "start_date": "2017-10-01",
      "completion_date": "2021-10-01",
      "has_results": false,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-10-26T11:30:50.587Z",
      "location_count": 5,
      "location_summary": "Towson, Maryland • Omaha, Nebraska • Syracuse, New York + 2 more",
      "locations": [
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Springfield",
          "state": "Oregon"
        },
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03414437"
    },
    {
      "nct_id": "NCT04875702",
      "title": "Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "Allopurinol",
          "type": "DRUG"
        },
        {
          "name": "Naproxen 250 MG",
          "type": "DRUG"
        },
        {
          "name": "Colchicine 0.6 mg",
          "type": "DRUG"
        },
        {
          "name": "Colchicine 1.2 mg",
          "type": "DRUG"
        },
        {
          "name": "Naproxen 500 Mg",
          "type": "DRUG"
        },
        {
          "name": "Prednisone 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 650,
      "start_date": "2024-02-22",
      "completion_date": "2028-10-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-10-26T11:30:50.587Z",
      "location_count": 7,
      "location_summary": "South Birmingham, Alabama • Santa Monica, California • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "South Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04875702"
    },
    {
      "nct_id": "NCT01746173",
      "title": "CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "T-cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Plerixafor",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Palifermin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 5,
      "start_date": "2013-07",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2023-01-30",
      "last_synced_at": "2026-10-26T11:30:50.587Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01746173"
    }
  ]
}